FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
MedPage Today1d
1 in 5 Adults Report Anxiety, Depression; Esketamine Label Update; Autism Dx Up 175%
The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...
HealthDay on MSN1d
Psychedelics Like Psilocybin, MDMA Tied to Higher Odds for Schizophrenia
People are at higher risk of schizophrenia if they indulge in psychedelic drugs, a new study warns. Patients who land in the ER following hallucinogen use have a 21-fold higher risk of developing ...
Neuroscience News1d
Schizophrenia Risks Tied to Psychedelic Use
A new study links hallucinogen-related emergency department visits to a 21-fold increased risk of schizophrenia compared to ...
Psychedelic use linked to increased risk of schizophrenia, study finds
Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...
MarketWatch1d
This biotech’s stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Its pipeline includes treatments for bipolar depression, agitation in Alzheimer’s disease, schizophrenia and Parkinson’s ...
Taking drugs like LSD and ecstasy can increase your risk of schizophrenia, according to new study
Psychedelics have been growing in popularity across North America for recreational and therapeutic use, with celebrities like ...
AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say
AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...
BioPharma Dive3d
On Wall Street, ‘flat out’ failure of AbbVie schizophrenia drug leaves analysts stunned
Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...
Crain's Chicago Business3d
AbbVie tumbles after new schizophrenia drug fails trials
AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...
Why AbbVie Stock Was Getting Mashed on Monday
Cerevel wasn't a one-trick pony, however. For its considerable spend, AbbVie also acquired several other pipeline programs from the neuroscience-focused biotech. The most promising of these is ...
Morningstar3d
Bristol Myers Squibb's stock soars after rival AbbVie reports disappointing schizophrenia-drug trial
AbbVie said it was disappointed with the results of its emraclidine trial for treating schizophrenia Bristol Myers Squibb Co. shares surged on Monday after rival AbbVie Inc. reported disappointing ...